JP2023082086A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023082086A5 JP2023082086A5 JP2023052465A JP2023052465A JP2023082086A5 JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5 JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023052465 A JP2023052465 A JP 2023052465A JP 2023082086 A5 JP2023082086 A5 JP 2023082086A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- powder
- ray diffraction
- pharmaceutical composition
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610866253.6 | 2016-09-29 | ||
| CN201610866253 | 2016-09-29 | ||
| JP2019538551A JP7253491B2 (ja) | 2016-09-29 | 2017-09-29 | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 |
| PCT/CN2017/104506 WO2018059556A1 (zh) | 2016-09-29 | 2017-09-29 | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538551A Division JP7253491B2 (ja) | 2016-09-29 | 2017-09-29 | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023082086A JP2023082086A (ja) | 2023-06-13 |
| JP2023082086A5 true JP2023082086A5 (https=) | 2023-07-28 |
| JP7763203B2 JP7763203B2 (ja) | 2025-10-31 |
Family
ID=61763329
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538551A Active JP7253491B2 (ja) | 2016-09-29 | 2017-09-29 | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 |
| JP2023052465A Active JP7763203B2 (ja) | 2016-09-29 | 2023-03-28 | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538551A Active JP7253491B2 (ja) | 2016-09-29 | 2017-09-29 | キナーゼ阻害剤化合物の結晶多形、それを含む医薬組成物及びその製造方法と応用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11053224B2 (https=) |
| EP (1) | EP3502105B8 (https=) |
| JP (2) | JP7253491B2 (https=) |
| KR (1) | KR102289684B1 (https=) |
| CN (1) | CN108884080B (https=) |
| AU (1) | AU2017336889B2 (https=) |
| CA (2) | CA3253105A1 (https=) |
| EA (1) | EA201990688A1 (https=) |
| ES (1) | ES2914294T3 (https=) |
| IL (2) | IL265266B2 (https=) |
| MY (1) | MY194364A (https=) |
| PH (1) | PH12019500681A1 (https=) |
| PL (1) | PL3502105T3 (https=) |
| SG (1) | SG11201901962QA (https=) |
| TW (1) | TWI647224B (https=) |
| WO (1) | WO2018059556A1 (https=) |
| ZA (1) | ZA201901717B (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL265266B2 (en) * | 2016-09-29 | 2024-08-01 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| EP4210682B1 (en) | 2020-09-14 | 2026-03-25 | EyePoint, Inc. | Bioerodible ocular drug delivery insert and therapeutic method |
| WO2022197104A1 (ko) * | 2021-03-16 | 2022-09-22 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형 |
| JP7138982B1 (ja) | 2021-09-24 | 2022-09-20 | 東海物産株式会社 | アンセリンの結晶及びその製造方法 |
| WO2023173088A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | Method of preventing age-related macular degeneration by administering an ocular drug delivery insert |
| CA3245209A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | CONTINUOUS DOSAGE REGIMEN FOR THE TREATMENT OF AN EYE CONDITION |
| CA3245207A1 (en) | 2022-03-11 | 2023-09-14 | EyePoint Pharmaceuticals, Inc. | TREATMENT METHOD FOR MOISTURE-RELATED MACULAR DEGENERATION |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| CN117143083B (zh) * | 2023-08-30 | 2026-02-27 | 沈阳药科大学 | VEGFR抑制剂Vorolanib的合成方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003031438A1 (en) | 2001-10-10 | 2003-04-17 | Sugen, Inc. | 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| KR101507375B1 (ko) * | 2006-09-15 | 2015-04-07 | 엑스커버리 홀딩 컴퍼니 엘엘씨 | 키나아제 억제제 화합물 |
| US20110026367A1 (en) * | 2007-05-07 | 2011-02-03 | Baumer Electric Ag | Acoustic Transducer |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| KR20100135910A (ko) * | 2008-04-16 | 2010-12-27 | 낫코 파마 리미티드 | 수니티닙 염기의 신규한 다형 형태 |
| EP2292613B1 (en) * | 2008-05-23 | 2015-09-30 | Shanghai Institute of Pharmaceutical Industry | Dihydroindolinone derivatives |
| EP2186809A1 (en) | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| EP2264027A1 (en) * | 2009-05-27 | 2010-12-22 | Ratiopharm GmbH | Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| CN106928114B (zh) * | 2015-12-31 | 2020-07-28 | 韶远科技（上海)有限公司 | 含有脲基的环状手性氨基类化合物及其可放大工艺和用途 |
| IL265266B2 (en) * | 2016-09-29 | 2024-08-01 | Equinox Sciences Llc | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof |
-
2017
- 2017-09-29 IL IL265266A patent/IL265266B2/en unknown
- 2017-09-29 CN CN201780008042.1A patent/CN108884080B/zh active Active
- 2017-09-29 MY MYPI2019000596A patent/MY194364A/en unknown
- 2017-09-29 EA EA201990688A patent/EA201990688A1/ru unknown
- 2017-09-29 CA CA3253105A patent/CA3253105A1/en active Pending
- 2017-09-29 CA CA3035124A patent/CA3035124C/en active Active
- 2017-09-29 WO PCT/CN2017/104506 patent/WO2018059556A1/zh not_active Ceased
- 2017-09-29 ES ES17855006T patent/ES2914294T3/es active Active
- 2017-09-29 SG SG11201901962QA patent/SG11201901962QA/en unknown
- 2017-09-29 PL PL17855006T patent/PL3502105T3/pl unknown
- 2017-09-29 JP JP2019538551A patent/JP7253491B2/ja active Active
- 2017-09-29 TW TW106133830A patent/TWI647224B/zh active
- 2017-09-29 US US16/338,357 patent/US11053224B2/en active Active
- 2017-09-29 EP EP17855006.7A patent/EP3502105B8/en active Active
- 2017-09-29 KR KR1020197008752A patent/KR102289684B1/ko active Active
- 2017-09-29 AU AU2017336889A patent/AU2017336889B2/en active Active
-
2019
- 2019-03-19 ZA ZA201901717A patent/ZA201901717B/en unknown
- 2019-03-28 PH PH12019500681A patent/PH12019500681A1/en unknown
-
2021
- 2021-06-15 US US17/348,482 patent/US12209080B2/en active Active
-
2023
- 2023-03-28 JP JP2023052465A patent/JP7763203B2/ja active Active
-
2024
- 2024-03-20 IL IL311631A patent/IL311631B1/en unknown
-
2025
- 2025-01-27 US US19/038,129 patent/US20250188063A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023082086A5 (https=) | ||
| JP2021530565A5 (https=) | ||
| JP2020512316A5 (https=) | ||
| JP2009521414A5 (https=) | ||
| CN115698019A (zh) | 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法 | |
| JP2022183220A5 (https=) | ||
| JP2005503386A5 (https=) | ||
| JP2023002516A5 (https=) | ||
| KR100757699B1 (ko) | 순수한 결정형의 5-클로로-3-(4-메탄설포닐페닐)-6'-메틸-[2,3']비피리디닐 및 이의 합성 방법 | |
| JP2023036708A5 (https=) | ||
| JP2017061526A5 (https=) | ||
| JP2019504103A5 (https=) | ||
| JP2013538849A5 (https=) | ||
| JP2019516749A5 (https=) | ||
| JP2007532560A5 (https=) | ||
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| CN102964384B (zh) | 阿德福韦酯没食子酸共晶及其制备方法和组合物 | |
| JP2025102940A5 (https=) | ||
| JP2011515421A5 (https=) | ||
| JP2016510767A5 (https=) | ||
| JP2017503016A5 (https=) | ||
| JP2020533412A5 (https=) | ||
| CA2447878C (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JPWO2020118113A5 (https=) | ||
| JP2019500385A5 (https=) |